The Lab Meets the Living Room at RareNet

MIT's new rare brain disorders hub is betting that patient stories and genetic medicine belong in the same room — and on the same timeline.

By The Neurotech Desk

Monica Coenraads did not set out to become a research strategist. In 1998, her daughter Chelsea was diagnosed with Rett syndrome at age two, and Coenraads faced an uncertain future. [1] Today, as founder and CEO of the Rett Syndrome Research Trust, she is helping to rewrite that story for other families — and eventually took the stage at MIT to share both the scientific breakthroughs reshaping Rett syndrome treatment and the deeply personal journey that sparked it all.

Coenraads was one of the headline speakers at RareNet 2026, a symposium convened on June 9 at the McGovern Institute. [1] The event was described by organisers as a first-of-its-kind gathering aimed at dismantling the barriers between laboratory discovery and life-changing treatments for rare brain disorders. [1] Over 300 million people worldwide live with rare disorders — most affecting the brain and nervous system — and yet the vast majority lack an approved therapy. [1]

That gap between what science can imagine and what medicine can deliver is not a new problem. It is, however, one that has proved stubbornly resistant to good intentions alone. What changes the equation, advocates argue, is architecture: building the connective tissue between disciplines before the urgency of a single patient forces improvisation.

RareNet — formally the Rare Brain Disorders Nexus — was established at the McGovern Institute in 2025 by MIT alums Ana Méndez '91 and Jayavant '86, (EE '88, SM '88). [1] Led by Guoping Feng, the James W. (1963) and Patricia T. Poitras Professor of Neuroscience at MIT, the organisation draws together expertise from the MIT community and beyond to expedite the path from lab to clinic. [1]

MIT President Sally Kornbluth set the tone at the inaugural RareNet symposium, thanking founders Méndez and Jayavant and articulating the institutional ambition clearly: "I look forward to watching RareNet dissolve needless barriers, accelerate timelines, and bring new hope to millions of patients and their families for whom hope is long overdue." [1] It was a statement calibrated not for a press release but for the scientists and families who had flown in to hear it.

The language of translation has become familiar in academic medicine — sometimes suspiciously so. But there is a meaningful difference between institutions that invoke the lab-to-clinic journey as aspiration and those that design an entire organisational structure around removing the specific friction points that slow it down. The question RareNet is trying to answer is whether you can engineer that difference from the start.

The scientific programme made the scope of the challenge concrete. Feng Zhang of the McGovern Institute, MIT, HHMI, and the Broad Institute, Katherine High of RhyGaze AG and Rockefeller University, Kiran Musunuru of the University of Pennsylvania, and Timothy Yu of Boston Children's Hospital and Harvard Medical School each addressed emerging genetic medicines — genome editing, gene therapy, and individualised therapeutic strategies — and the challenges involved in bringing them safely to patients. [1] These are not theoretical tools. Several are already in or approaching clinical trials for conditions that, until recently, offered families nothing.

A second panel drilled into the biological foundations that make those therapies possible. Kevin Bender of UCSF, Christopher Walsh of Boston Children's Hospital and Harvard Medical School, Sonia Vallabh of the Broad Institute, MGH, and Harvard Medical School, and Joseph Buxbaum of the Icahn School of Medicine at Mount Sinai explored how insights into disease mechanisms, human genetics, and patient-derived data are advancing research in neurodevelopmental disorders, autism, and prion disease. [1] Vallabh's own story — she carries the mutation for fatal familial insomnia and has spent years researching her way toward a potential treatment — gave the session an edge that no abstract could replicate.

What distinguished RareNet 2026 from an ordinary conference was not the roster — though the roster was formidable — but the deliberate mixing of registers. Basic scientists sat through patient advocacy sessions. Patient advocates were handed detailed mechanistic data. The implicit argument was that proximity, repeated and structured, produces something that neither group generates alone.

That argument was made most explicitly by the patient community representatives. Karen Ball, Matt Shirley, and Samit Dasgupta — representing the Sturge-Weber and FOXP1 communities — demonstrated how patient foundations can help define research priorities, build essential resources, and drive promising discoveries toward meaningful treatments. [1] These are communities organised around disorders so rare that no pharmaceutical company has ever considered them commercially viable. The foundations have, in effect, become the R&D departments that the market will not fund.

[1] Gao added: "It's a powerful reminder that behind every research breakthrough is a human story demanding progress." [1] For Coenraads, who has spent more than two decades navigating the distance between a diagnosis and a treatment, the symposium represented something she has long argued for: a room where the urgency of a parent and the rigour of a molecular biologist are treated as equally necessary inputs.

The question that follows every gathering like this one is whether the energy survives the return flight. Symposia are good at generating connection and poor at sustaining it. Whether RareNet's institutional design — the staffed nexus, the named leadership, the MIT infrastructure behind it — proves adequate to that challenge will take years to assess. What the June event demonstrated is that the appetite is real, and the people who would benefit from faster progress are no longer content to wait in separate rooms.

RareNet's next steps have not yet been announced, but the McGovern Institute has signalled that the June symposium was a beginning, not a capstone. [1] For the 300 million people worldwide living with rare disorders — and the researchers who have chosen to work on problems the market ignores — the difference between a first-of-its-kind meeting and a durable institution is precisely the thing worth watching.

I look forward to watching RareNet dissolve needless barriers, accelerate timelines, and bring new hope to millions of patients and their families for whom hope is long overdue.Sally Kornbluth